BioPharma
Partner with BioSkryb to pair ResolveOME data generation with ResolveAI copilots, accelerating target discovery, biomarker strategy, and translational readouts.
AI-driven discovery engine
Capture high-fidelity single-cell DNA and RNA to power models that identify cell states, variants, and pathway activity linked to therapeutic response.
- Mechanism-of-action insights that trace heterogeneity back to genomic events.
- Early signal detection for resistance, toxicity, or patient stratification.
- Comparative analyses across cohorts to prioritize the right assets faster.
Regulatory-ready evidence
ResolveServices couples rigorous laboratory SOPs with model-backed QC to deliver reproducible packages that fit IND-enabling and translational milestones.
- Documented controls, chain-of-custody, and performance metrics.
- Explainable model outputs that support cross-functional review.
- Data structures ready for integration into bioinformatics and clinical systems.
Flexible partnering models
Engage through fee-for-service studies, platform pilots, or deeper collaborations that combine BioSkryb domain experts with your therapeutic leadership.
- Co-design roadmaps with milestones tied to discovery or translational gates.
- Jointly review AI findings to refine targets, biomarkers, or clinical hypotheses.
- Scale from exploratory work to multi-site programs without rebuilding infrastructure.
Ready to talk?
Contact us Explore how AI-enabled BioPharma partnerships can accelerate your next milestone.